Covishield received 16 percent of the antibodies per second dose: Analysis of the Covishield by ICMR.
Covishield received 16 percent of the antibodies. The Indian Council of Medical Research conducted a study on the performance analysis of the Covishield vaccine on the delta variant. Antibodies were not found to be neutralized in the blood samples of 58.1% of those who took the Covishield. None of the 16 percent who took both doses completely was neutralized.
It was realized that a large number of antibodies were being neutralized in the body due to the infection that comes with the vaccine. ‘Failure to do so means that there are no antibodies. None of the antibodies appeared in the tests due to lack of. Otherwise, the vaccinated person will be protected from infection and other diseases. Some cells mediate and provide protective immunity and protect against infection.
Antibodies neutralize and protect the Sars-CoV2 virus from killing or entering the human cell. However, they work much less on the Delta variant than on the B1 variant. Covishield works 78 percent of vaccine efficacy on the first dose of the Delta variant, 69 percent of those taking the two doses, 66 percent of those taking the vaccine after infection, and 38 percent of those taking the two-dose vaccine after infection.
ICMR conducted the study with the serum of healthy people who had been vaccinated .. observed the activity of unpredictable antibodies. In the elderly, antibodies are more likely to be produced in people with chronic problems and those with a lower immune response. This means that antibodies are more likely to be produced in women than in men.
People over the age of 65 who are on diabetes, hypertension, chronic heart, Respiratory organs, kidney problems, cancer treatment should also take the third dose. Said Jacob John.